scholarly journals A comparison of COVID-19, SARS and MERS

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9725 ◽  
Author(s):  
Tingting Hu ◽  
Ying Liu ◽  
Mingyi Zhao ◽  
Quan Zhuang ◽  
Linyong Xu ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Case Fatality ◽  
Hubei Province ◽  
World Health ◽  
Atypical Pneumonia ◽  
Organization Studies ◽  
Optimal Method ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

In mid-December 2019, a novel atypical pneumonia broke out in Wuhan, Hubei Province, China and was caused by a newly identified coronavirus, initially termed 2019 Novel Coronavirus and subsequently severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 19 May 2020, a total of 4,731,458 individuals were reported as infected with SARS-CoV-2 among 213 countries, areas or territories with recorded cases, and the overall case-fatality rate was 6.6% (316,169 deaths among 4,731,458 recorded cases), according to the World Health Organization. Studies have shown that SARS-CoV-2 is notably similar to (severe acute respiratory syndrome coronavirus) SARS-CoV that emerged in 2002–2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) that spread during 2012, and these viruses all contributed to global pandemics. The ability of SARS-CoV-2 to rapidly spread a pneumonia-like disease from Hubei Province, China, throughout the world has provoked widespread concern. The main symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, myalgia, fatigue and lower respiratory signs. At present, nucleic acid tests are widely recommended as the optimal method for detecting SARS-CoV-2. However, obstacles remain, including the global shortage of testing kits and the presentation of false negatives. Experts suggest that almost everyone in China is susceptible to SARS-CoV-2 infection, and to date, there are no effective treatments. In light of the references published, this review demonstrates the biological features, spread, diagnosis and treatment of SARS-CoV-2 as a whole and aims to analyse the similarities and differences among SARS-CoV-2, SARS-CoV and MERS-CoV to provide new ideas and suggestions for prevention, diagnosis and clinical treatment.

scholarly journals COVID-19 Mimicking Acute Colitis

2021 ◽  
Vol 96 (2) ◽  
pp. 143-146
Author(s):  
Jaeseok Park ◽  
Jaekwon Jung ◽  
Hyunsoo Kim ◽  
Changkeun Park ◽  
Daejin Kim ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Clinical Picture ◽  
Hubei Province ◽  
World Health ◽  
Acute Colitis ◽  
The World ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

On 11 February, 2020, the World Health Organization announced that COVID-19 was a novel coronavirus disease first detected in Wuhan, Hubei Province, China. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The complete clinical picture is not fully known. Illness ranges from mild to fatal. The common symptoms include fever, cough, and dyspnea usually developing 2-14 days after exposure. However, diarrhea was present in a few patients with COVID-19. We report a case of COVID-19 mimicking acute colitis.

Current updates on COVID-19 - A review

2020 ◽  
Vol 10 (1) ◽  
pp. 1-8
Author(s):  
Ghotekar D S ◽  
Vishal N Kushare ◽  
Sagar V Ghotekar
Keyword(s):  
World Health Organization ◽  
Common Cold ◽  
Respiratory Diseases ◽  
Gastrointestinal Diseases ◽  
Hubei Province ◽  
World Health ◽  
The World ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).

scholarly journals A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19

2020 ◽  
Vol 25 (10) ◽  
pp. 1108-1122 ◽  
Author(s):  
Dawid Maciorowski ◽  
Samir Z. El Idrissi ◽  
Yash Gupta ◽  
Brian J. Medernach ◽  
Michael B. Burns ◽  
...  
Keyword(s):  
Gastrointestinal Symptoms ◽  
High Risk Group ◽  
Capital City ◽  
World Health ◽  
Atypical Pneumonia ◽  
Live Animal ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

In December of 2019, an outbreak of a novel coronavirus flared in Wuhan, the capital city of the Hubei Province, China. The pathogen has been identified as a novel enveloped RNA beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus SARS-CoV-2 is associated with a disease characterized by severe atypical pneumonia known as coronavirus 2019 (COVID-19). Typical symptoms of this disease include cough, fever, malaise, shortness of breath, gastrointestinal symptoms, anosmia, and, in severe cases, pneumonia.1 The high-risk group of COVID-19 patients includes people over the age of 60 years as well as people with existing cardiovascular disease and/or diabetes mellitus. Epidemiological investigations have suggested that the outbreak was associated with a live animal market in Wuhan. Within the first few months of the outbreak, cases were growing exponentially all over the world. The unabated spread of this deadly and highly infectious virus is a health emergency for all nations in the world and has led to the World Health Organization (WHO) declaring a pandemic on March 11, 2020. In this report, we consolidate and review the available clinically and preclinically relevant results emanating from in vitro animal models and clinical studies of drugs approved for emergency use as a treatment for COVID-19, including remdesivir, hydroxychloroquine, and lopinavir-ritonavir combinations. These compounds have been frequently touted as top candidates to treat COVID-19, but recent clinical reports suggest mixed outcomes on their efficacies within the current clinical protocol frameworks.

scholarly journals Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate

Medicina ◽  
2020 ◽  
Vol 56 (10) ◽  
pp. 506 ◽  
Author(s):  
Pierpaolo Di Micco ◽  
Vincenzo Russo ◽  
Corrado Lodigiani
Keyword(s):  
Venous Thromboembolism ◽  
Severe Acute Respiratory Syndrome ◽  
World Health ◽  
Diagnostic Tools ◽  
Unknown Etiology ◽  
The World ◽  
Open Debate ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Pharmacological Thromboprophylaxis

Asreported by the World Health Organization, a novel coronavirus (COVID-19) was identified as the causative virus of new viral pneumonia of unknown etiology by Chinese authorities on 7 January 2020. The virus was named COVID-19 and because of its ability to cause severe acute respiratory syndrome (i.e., SARS) this infection has also been defined as SARS-CoV2.Furthermore, an association between COVID-19 infection and venous thromboembolism has been reported in several series around the world.For this reason, methods used to improve diagnostic tools, pharmacological thromboprophylaxis and type of anticoagulants are discussed in this expert opinion.

scholarly journals SARS update 11 April - Compelling evidence for aetiology, WHO team report from China, global epidemiology, and EU index and guidance

2003 ◽  
Vol 7 (15) ◽  
Author(s):  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Online Publication ◽  
World Health ◽  
Compelling Evidence ◽  
Interim Report ◽  
Global Epidemiology ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

Several articles on the identification of a novel coronavirus thought to have a role in causing severe acute respiratory syndrome (SARS) have been given early online publication this week (1-5), and the World Health Organization (WHO) has published an interim report from the WHO team of experts currently investigating the outbreak in China (7).

scholarly journals Oral medicine, oral pathology and coronavirus (2019-nCoV)

2020 ◽  
Vol 19 ◽  
pp. e200001
Author(s):  
Hercílio Martelli-Júnior ◽  
Renato Assis Machado ◽  
Daniella R. Barbosa Martelli ◽  
Ricardo Della Coletta
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Causative Agent ◽  
Oral Pathology ◽  
World Health ◽  
Oral Medicine ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

In late December 2019, a cluster of unexplained pneumonia cases was diagnosed in Wuhan, China, and few days later, the causative agent of this mysterious pneumonia was identified as a novel coronavirus. This causative virus has been temporarily named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the relevant infected disease has been named as coronavirus disease 2019 (COVID-19) by the World Health Organization respectively. The COVID-19 epidemic is spreading in China and all over the world now...

scholarly journals Severe Acute Respiratory Syndrome – update

2003 ◽  
Vol 7 (12) ◽  
Author(s):  
A C de Benoist ◽  
D Boccia
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
World Health ◽  
Atypical Pneumonia ◽  
Unknown Aetiology ◽  
Case Definitions ◽  
Health Threat ◽  
The World ◽  
Health Organization

On 15 March 2003, the World Health Organization (WHO) stated that the Severe Acute Respiratory Syndrome (SARS), an atypical pneumonia of unknown aetiology, is now “a worldwide health threat” (1). As of 19 March, 264 suspect and probable cases have been reported to WHO since 1 February 2003 (2). The surveillance case definitions have been modified (table).

scholarly journals Impact of COVID-19 on several industries in context with the telehealth and telemedicine industry

2021 ◽  
Vol 2 (4) ◽  
pp. 01-02
Author(s):  
Ashish Gujrathi
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Hubei Province ◽  
World Health ◽  
Growth Opportunities ◽  
Wuhan City ◽  
First Case ◽  
The World ◽  
New Challenges ◽  
Health Organization

Coronavirus (COVID-19) was recognized in late December in Hubei province of Wuhan city in China. This highly contagious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from humans to humans. After the first case in Wuhan, the disease rapidly spread to other parts of the globe. On March 11, 2020, the World Health Organization (WHO) made an assessment that COVID-19 can be characterized as a pandemic. Thus, social-distancing became an important measure to stop the spread of this disease. Various countries across the world adopted nationwide lockdowns. This led to a completely new scenario for the world, where every business in each industry faced new challenges and witnessed new opportunities. Similarly, the telehealth and telemedicine industry has also witnessed newer growth opportunities.

scholarly journals Laboratory investigations into the aetiological agent of severe acute respiratory syndrome (SARS)

2003 ◽  
Vol 7 (17) ◽  
Author(s):  
A Bermingham ◽  
Joanne Stockton ◽  
J Ellis
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
World Health ◽  
Network Member ◽  
Atypical Pneumonia ◽  
Diagnostic Assay ◽  
Bacterial Cultures ◽  
The World ◽  
Laboratory Investigations ◽  
Health Organization ◽  
Antibody Tests

On 17 March 2003, the World Health Organization (WHO) established a multicentre network of leading laboratories from 10 countries, to research the aetiology of severe acute respiratory syndrome (SARS) and to develop a robust and reliable diagnostic test. The methods utilised and the results of the network member laboratories have been shared on a secure web site and via frequent teleconferences, enabling investigative approaches for detecting the causative agent of SARS to be continually refined and to develop a diagnostic assay. Initial microbiological investigations aimed to detect a range of viral and bacterial agents known to cause atypical pneumonia. The methodologies employed included electron microscopy (EM), immunofluorescent antibody tests (IFA), viral and bacterial cultures, and a range of molecular based assays.

scholarly journals Severe Acute Respiratory Syndrome: international update

2003 ◽  
Vol 7 (14) ◽  
Author(s):  
P Horby ◽  
A Nicoll
Keyword(s):  
Hong Kong ◽  
Severe Acute Respiratory Syndrome ◽  
Case Fatality ◽  
Guangdong Province ◽  
World Health ◽  
The United Kingdom ◽  
Current Transmission ◽  
The World ◽  
Health Organization ◽  
Local Transmission

As of 2 April 2003, 2223 cases of Severe Acute Respiratory Syndrome (SARS) and 78 deaths have been reported to the World Health Organization (WHO), a case fatality rate of 3.5% (http://www.who.int/csr/sarscountry/2003_04_02/en/). This is an increase of four to fivefold in the global totals in the last seven days (http://www.who.int/csr/sarscountry/2003_03_25/en/) with the greatest proportionate and absolute increases being in China (Hong Kong and Guangdong Province), and to a much lesser extent in Canada. There has been little absolute rise in other country totals. Eighteen countries have now reported cases but in most of these no transmission seems to have occurred. Local transmission has occurred in Hanoi (Vietnam), Singapore, Toronto (Canada), Taiwan, and the following parts of China: Guangdong Province; Beijing; Shanxi; and the special administrative region of Hong Kong. In the United Kingdom three probable SARS cases have been reported; all have now recovered. Indeed, the only areas where WHO feels there is evidence consistent with current transmission are Hong Kong and Guangdong (http://www.who.int/csr/sarsarchive/2003_02_02b/en/), and the WHO has issued advice to international travellers not to travel to or through either area.

Sign in / Sign up

Export Citation Format

Share Document